Long-term Study of Cariprazine in Patients With Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01104792
Recruitment Status : Completed
First Posted : April 15, 2010
Last Update Posted : April 25, 2014
Gedeon Richter Ltd.
Information provided by (Responsible Party):
Forest Laboratories

Brief Summary:
The objective of this study is to evaluate the long-term safety, tolerability and pharmacokinetics of cariprazine in patients with schizophrenia.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: Cariprazine Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 588 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Long-Term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients With Schizophrenia
Study Start Date : April 2010
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Cariprazine flexible dose, oral administration once daily for 48 weeks
Drug: Cariprazine
Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
Other Name: RGH-188

Primary Outcome Measures :
  1. Safety: adverse event recording, clinical laboratory parameters, vital signs, electrocardiograms and other [ Time Frame: 48 weeks ]

Secondary Outcome Measures :
  1. Pharmacokinetics: Plasma concentrations of cariprazine and its metabolites [ Time Frame: 48 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients and corresponding caregivers who have provided informed consents prior to any study specific procedures
  • Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID)
  • Patients with normal physical examination, laboratory, vital signs and electrocardiogram (ECG)

Exclusion Criteria:

  • Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform disorder, bipolar I or bipolar II disorder, or psychotic disorders other than schizophrenia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01104792

  Show 86 Study Locations
Sponsors and Collaborators
Forest Laboratories
Gedeon Richter Ltd.
Study Director: Raffaele Migliore, MA Forest Laboratories

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Forest Laboratories Identifier: NCT01104792     History of Changes
Other Study ID Numbers: RGH-MD-11
First Posted: April 15, 2010    Key Record Dates
Last Update Posted: April 25, 2014
Last Verified: March 2014

Keywords provided by Forest Laboratories:
Acute Schizophrenia
Psychotropic Drugs
Antipsychotic Agents
Mental Disorders
Dopamine Agents
Central Nervous System Agents

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders